Clinical trial
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the…
NCT00435084 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00435084 |
|---|---|
| Title | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL |
| Official title | An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | APO866 |
| Enrollment | 10 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Feb 14, 2007 |
| Last update posted | Sep 23, 2015 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: